What does this research mean for the field?

A simulated, LLM-controlled 8-arm robotic system can theoretically execute a 60-second pancreaticoduodenectomy with high precision, outperforming simulated successors to current robotic platforms. Novelty: ClaimNovelty.METHODOLOGICAL. Consensus alignment: ConsensusAlignment.ESTABLISHES_NEW_DIRECTION.

What question did this study set out to answer?

This research aims to explore the integration of AI-driven robotic systems in performing pancreaticoduodenectomy quickly and efficiently using a KRAS inhibitor.

May 17, 20260 citationsOpen Access

View Full Paper

2030: 60 Second Pancreatic Ductal Adenocarcinoma Robotic Whipple Procedure & Daraxonrasib Simulation

KKKevin Kawchak

Key Points

This research aims to explore the integration of AI-driven robotic systems in performing pancreaticoduodenectomy quickly and efficiently using a KRAS inhibitor.
Developed an 8-arm robotic pancreaticoduodenectomy simulation using a large language model workflow.
Conducted a deterministic Latin hypercube sweep with 32 iterations to assess performance metrics of the robotic system.
Analyzed real-time sensor data controlling treatment administration through precise coordinates.
Achieved a mean composite performance score of 93.298, with the top system scoring 93.735 compared to predecessors.
Demonstrated a postoperative restart distribution of Daraxonrasib at T+7d in 29 of 32 iterations.
Highlighted the need for advancements to bridge technological gaps for practical adoption.

Abstract

On premises repository based large language models (LLMs) provide commands to a parallel coelomic oncology robot based on real time sensor data that is controlled via x, y, z coordinates to administer patient treatment and minimize error. This thesis was first initiated through a five phase Claude Code workflow (create instructions, generate code, code execution, draft generation, and full paper production) yielding a 60 second 8 arm robotic pancreaticoduodenectomy on a hypothetical 2030 Medtronic PancreSpeed 1. 0 platform paired with the Daraxonrasib pan KRAS inhibitor (FDA Breakthrough Therapy 06/25, RASolute 302 + RASolve 301). PancreSpeed 1. 0 closes a 5x to 500x SOTA gap (1, 200 mm/s tip, 100 kHz force, 0. 05 mm RMS, 3 ms E stop, 18 N cumulative cap, 640 sensor channels). A 32 iteration deterministic Latin hypercube sweep at seed 20260513 yields mean composite 93. 298 (std 1. 225, 95% CI half width 0. 462), and the 4 entrant LLM tournament places PancreSpeed 1. 0 first at 93. 735 versus 2030 da Vinci SP and Hugo RAS successors. The 1001 record Phase 5 first 100 ms sensorₛample_- 8arm. jsonl is an exceptional processing feat; Daraxonrasib postop restart distributes as T+7d in 29 of 32 iterations. Practical adoption still requires bridging the synthetic patient gap, hypothetical hardware gap, and TRIPOD+AI plus CREMLS reporting floors.

Demander à l'IA

Bookmark

View Full Paper

Demander à l'IA

Bookmark

View Full Paper

2030: 60 Second Pancreatic Ductal Adenocarcinoma Robotic Whipple Procedure & Daraxonrasib Simulation

Key Points

Abstract

Cite This Study